Clinical trials located in

Genk

Genk city is located in Belgium. Currently, 19 clinical trials are being conducted in this city.

Genk, located in the Belgian province of Limburg, is a vibrant city known for its rich industrial past, particularly in coal mining. This history is celebrated at the C-Mine cultural center, a transformed coal mine site. Genk is also home to the beautiful Bokrijk Open-Air Museum, showcasing Belgian life through the ages with authentic buildings and live demonstrations. The city is a melting pot of cultures, reflected in its diverse culinary scene and numerous community events. Additionally, Genk boasts the Hoge Kempen National Park, a haven for nature enthusiasts.

  • CT-EU-00116671

    Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    BelgiumDenmarkFranceGermanyGreeceItalyPolandPortugalSpainSwedenUnited Kingdom
  • A study comparing upadacitinib versus adalimumab in the treatment of rheumatoid arthritis

    This clinical trial is studying a new medication called upadacitinib for treating moderate to severe rheumatoid arthritis. Rheumatoid arthritis is a chronic condition that causes pain, stiffness, swelling, and loss of joint function. The study will compare upadacitinib, which is taken as an oral tablet once daily, to adalimumab (brand name Humira), which is an injection given under the skin every other week.

    The main goal is to see how effective upadacitinib is at reducing disease activity compared to adalimumab. The study will measure the percentage of participants who achieve a certain level of low disease activity based on a score called the DAS28-CRP, which looks at tender and swollen joints, overall disease activity, and inflammation levels.

    This is a double-blind study, meaning neither the participants nor the study doctors will know which treatment each participant is receiving. Participants will attend regular visits at a hospital or clinic for medical assessments, checking for side effects, and completing questionnaires. There may be a higher treatment burden compared to standard care. The study is designed to assess the safety and effectiveness of upadacitinib compared to adalimumab in treating moderate to severe rheumatoid arthritis.

    BelgiumBulgariaFranceGermanyGreeceHungaryItalyPortugalRomaniaSpainUnited Kingdom
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing personalized treatments for advanced prostate cancer

    ProBio is a worldwide study for patients with advanced prostate cancer. It will look at whether new treatments can help patients based on their unique cancer characteristics. Patients are allocated in two groups: one will receive usual care following local guidelines (control group). The other group will be given treatments designed specifically for their type of cancer. These treatments will be chosen based on their cancer’s unique characteristics – what is called ‘biomarker signatures’. Depending on how well they respond to the treatment, patients may be moved to different treatments. Each treatment will be compared to standard care for effectiveness. The researchers will decide if treatments are effective, should continue, or should be stopped. New types and combinations of treatments can be included in the future. The study will use well-established standards to assess cancer improvement. Quality of life and costs of the treatment will also be evaluated. Side effects and responses to treatment at 6 months will also be recorded.

    BelgiumNorwaySweden
  • Examining new drug efficiency in avoiding blood clots post knee surgery

    This study is trying to find out how good a medicine named REGN9933 is at preventing blood clots after a person has a single knee replacement. We compare how it works with another medicine called enoxaparin. The main goal of the study is to see if REGN9933 is better at stopping venous clotting after this surgery. The trial will be focused on checking on the chance of bleeding happening after the operation, and if REGN9933 is safe and easy to tolerate for people having knee replacement. The trial will show the new drug’s ability to prevent dangerous clots, and its impact on deep venous thrombosis, which is a clot deep within a vein. Also, it’s essential to understand how it’s absorbed, and how it affects natural clotting mechanisms in the human body and the immune response over time. The study will compare REGN9933 with enoxaparin and another medicine named apixaban.

    BelgiumBulgariaHungaryPoland
  • Testing new treatment for coagulation disorder

    The objective of this trial is to explore different methods of halting or reversing the blood-thinning effects of specific medications before an urgent surgery. The study compares two treatments: a new medicine named TAK-330 and a commonly used one called 4F-PCC. The goal is to determine which treatment is more effective. Participants in the study will be randomly assigned to receive either TAK-330 or 4F-PCC before their surgery, requiring a hospital stay. After the surgery, the research will assess how well the participants’ blood clotting functions during and after the procedure. The study will also monitor whether additional treatments were necessary to control bleeding. Any side effects or significant health changes will be tracked, and participants will be followed up for 30 days after the surgery to assess their recovery progress.

    BelgiumFranceNetherlandsSpain
  • Secukinumab study for maintaining remission in axial spondyloarthritis

    The aim of this study is to see if a drug called Secukinumab can maintain remission in people with non-radiographic axial spondyloarthritis (a type of spondylitis). Remission means that there is no or very little disease in the body. To determine whether a person is in remission, we use a special scoring system that looks at various symptoms of arthritis and a blood test for a protein associated with inflammation (C-reactive protein, or CRP). The aim of the study is to see whether people who stop taking Secukinumab will experience an exacerbation (worsening of the disease) and how long it takes for this to happen. The study will last just over two years.

    BelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomania
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Evaluating safety & effects of new therapy in Heart Failure

    This research focuses on investigating a new medication, REGN5381, for adults experiencing heart-related issues and considering a specialized heart procedure known as right heart catheterization, as recommended by the study’s doctor. The primary objectives include assessing the safety and tolerability of the study medicine, understanding the changes that may occur in the body due to its administration, measuring the concentration of the study medicine in the blood at different intervals, and examining whether the body generates defense mechanisms (antibodies) against the study medicine, potentially impacting its efficacy or causing physiological changes.

    BelgiumHungaryPolandRomania
  • Study on treating uncontrolled bleeding with bentracimab

    A trial investigating bentracimab’s ability to reverse ticagrelor’s effects in patients with severe bleeding or those needing urgent surgery. The study, involving at least 200 patients from various regions, tests if bentracimab can quickly counteract ticagrelor, improving patients’ conditions or allowing for safe surgeries. Patients receive a thorough follow-up to ensure the drug’s effectiveness and safety, aiming to provide a reliable treatment for critical, time-sensitive medical scenarios.

    AustriaBelgiumFranceGermanyItalyNetherlandsSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • A study of lanifibranor treatment in adults with nonalcoholic fatty liver disease

    This study is a two-part trial looking at how well a drug called Lanifibranor works for adults suffering from liver diseases known as NASH and fibrosis stages F2 and F3. In the first part of the trial, the researchers will compare the effects of Lanifibranor with a placebo, which is a substance with no medical effect. The researchers will be looking at how much the drug can improve the health of the liver. The second part of the study will continue the use of Lanifibranor to see if there are any long-term safety issues. Apart from studying the drug’s effectiveness in resolving NASH and reducing live fibrosis, the trial will also be observing how it affects other aspects of liver health, diabetes, blood sugar and fat levels, liver stiffness and patients’ quality of life.

    AustriaBelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing new medication and cetrelimab for Muscle-Invasive Bladder Cancer

    Bladder cancer ranks tenth among the most common cancers globally. About 25% of new cases involve aggressive muscle invasive bladder cancer (MIBC). The purpose of this study is to evaluate the antitumor effects of a new medication called AR-200 in combination with intravenous cetrelimab and cetrelimab alone. The study spans screening, treatment, and follow-up phases, lasting up to 2 years and 6 months. The research evaluates efficacy, safety, pharmacokinetics, and biomarkers at specific intervals.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing mavacamten’s effect on heart muscle in obstructive cardiomyopathy patients

    This study is intended to test the effects of the drug Mavacamten on the heart’s structure, specifically for participants with a condition called Symptomatic Obstructive Hypertrophic Cardiomyopathy. This condition causes the heart to not work as it should, leading to symptoms such as breathlessness and chest pain. To investigate this, doctors will use a special type of heart scan (Cardiac Magnetic Resonance Imaging or CMR). The researchers hope to see if Mavacamten can reduce heart enlargement and thickness (which are linked to this health condition) after 48 weeks of taking the medication. Participants are identified as successful if their heart scan shows a decrease in both heart size (at least 5 mL/m2) and thickness (at least 5 g/m2) compared to their initial measurements.

    AustriaBelgiumGermanyHungarySpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • The effectiveness of new medication for treating pain after surgery

    This study explores the use of AP-325 — an oral pain medication — in managing surgical pain. Participants will be individuals who’ve had various surgeries, for example, breast surgery, chest surgery, hernia repair, abdominal surgery, varicose vein surgery, or gynecological surgery. The study’s objective is to determine the effectiveness and safety of AP-325 in controlling the pain that usually follows these surgeries. For this purpose, participants take either AP-325 or a placebo once daily for 10 days. Later, they are monitored for an additional 26 days without the drug. Pain levels are evaluated using the Pain Intensity Numerical Rating Scale (PI-NRS), while overall health and wellbeing are judged through questionnaires assessing sleep quality, mood and quality of life. 

    BelgiumCzechiaFranceSpain

See more clinical trials in other cities in Belgium:

.